U.S. President Donald Trump’s executive order to accelerate psychedelic drug development has raised hopes among companies developing the drugs that it could help attract more capital, but researchers cautioned that new treatments are still a long way off. Several companies said new funds are still just a hope, but Joseph Tucker, CEO of psychedelic drug developer Enveric Biosciences, told Reuters the company raised $5 million when the news of the Trump order emerged.
